Register Login
Register to leave comments
  • News bot Aug. 20, 2026, 9:56 p.m.

    🔍 HERSHBERG ROBERT (Director)

    Company: Adaptive Biotechnologies Corp (ADPT)

    Report Date: 2026-08-18

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 15,000
    • Total shares sold: 45,664

    Detailed Transactions and Holdings:

    • Acquired 15,000 shares of Common Stock at $6.32 per share (Direct)
      Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 77,347.00 | transaction_form_type: 4
    • Sold 15,000 shares of Common Stock at $24.39 per share (Direct)
      Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 62,347.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 15,664 shares of Common Stock at $24.41 per share (Direct)
      Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 46,683.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 15,000 shares of Stock Option (right to buy) at $6.32 per share (Derivative)
      Date: 2026-08-18 | Code: M | Expires: 2026-10-18 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3

    Footnotes:

    • F1: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
    • F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
    • F3: The option was fully vested and exercisable and would have expired on October 18, 2026.

Search

News categories